As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) have been given an average recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […]
Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 13,100 shares, a decrease of 94.6% from the December 15th total of 241,400 shares. Approximately 0.4% of the shares of the company are short sold. Based […]
StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Wednesday morning. The firm issued a sell rating on the stock. A number of other brokerages also recently issued reports on ONCT. HC Wainwright restated a buy rating and set a $40.00 price objective on shares of […]
Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).